Ronald Peck
Geen lopende functies
Vermogen: 461 375 $ op 31-05-2024
Loopbaan van Ronald Peck
Eerdere bekende functies van Ronald Peck
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| ARVINAS, INC. | Hoofd Techniek/Wetenschap/O&O | 29-07-2019 | 18-03-2024 |
| TESARO INC | Hoofd Techniek/Wetenschap/O&O | 01-04-2017 | 01-07-2019 |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Hoofd Techniek/Wetenschap/O&O | 01-08-2015 | 01-12-2016 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01-12-2011 | 01-05-2015 |
| University of Virginia | Corporate Officer/Principal | 01-07-1997 | 01-02-2000 |
Opleiding van Ronald Peck
| Georgetown University | Undergraduate Degree |
| Sidney Kimmel Medical College | Doctorate Degree |
Statistieken
Internationaal
| Verenigde Staten | 8 |
Operationeel
| Chief Tech/Sci/R&D Officer | 3 |
| Corporate Officer/Principal | 2 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 5 |
| Consumer Services | 4 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ARVINAS, INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products. The firm offers Niraparib products. The company was founded by Leon Oliver Moulder, Jr., Mary Lynne Hedley, and Richard J. Rodgers on March 26, 2010 and is headquartered in Waltham, MA. | Health Technology |
Kolltan Pharmaceuticals, Inc.
Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
- Beurs
- Insiders
- Ronald Peck
- Ervaring
